Redx Pharma
Redx is a UK biotechnology Group whose shares are traded on AIM [AIM:REDX]. Redx is focused on creating and developing first-in-class, or potentially best-in-class drugs, in specific areas of cancer and fibrosis that address significant unmet medical need. Redx has an in-house discovery team with proven world-class chemistry capabilities.
Sector
Biopharmaceuticals
Strategies
Crossover
Status
Live
Website
www.redxpharma.com
Related News
Redx confirms changes to Board composition
Jazz Pharmaceuticals enters definitive agreement with Redx Pharma to acquire global rights to KRAS Inhibitor Program
Redx nominates GI-targeted ROCK Inhibitor, RXC008, as clinical development candidate
Redx Pharma raises £25.5M
Redx Pharma appoints Dr Jane Robertson as chief medical officer
Redx and Jazz Pharmaceuticals partner on two cancer targets
Tom Burt joins Redx Pharma board as Sofinnova non-executive director
Redx signs licensing agreement with AstraZeneca for RXC006
Redx Pharma proposes $30M financing via convertible loan notes
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.